Kamada makes management changes
This article was originally published in Scrip
Executive Summary
Kamada, a plasma-derived protein therapeutics company focused on orphan indications, has announced executive management changes intended to strengthen the company's leadership. Under the changes, David Tsur, co-founder and CEO, will become deputy executive chair of the board, a new position whereby he will maintain his strategic advisory role yet relinquish day-to-day management responsibilities. Leon Recanti will remain the chair of the board. Amir London, the company's senior vice-president of business development, will become CEO and Gil Efron, currently chief financial officer, will take on the added role of deputy CEO. The changes are expected to go into effect in July 2015.